BlackRock’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

BlackRock’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-233,178	Closed	-$4.45K	–	5703
2023 Q1	$4.45K	Sell	233,178 -3,517	-1%	-$339	﹤0.01%	5380
2022 Q4	$35.2K	Hold	236,695	–	–	﹤0.01%	5293
2022 Q3	$40K	Hold	236,695	–	–	﹤0.01%	5402
2022 Q2	$28K	Sell	236,695 -5,670	-2%	-$2.8K	﹤0.01%	5514
2022 Q1	$191K	Sell	242,365 -1,643	-0.7%	-$1.15K	﹤0.01%	5117
2021 Q4	$146K	Buy	+244,008	New	+$248K	﹤0.01%	5176

Other funds holding PEARW

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

BlackRock's PEARW Position: Q2 2023 in Review

BlackRock sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2023, closing a stake of 233,178 shares — an estimated $4.45K sold.

BlackRock first reported a position in PEARW in Q4 2021 and held it in 6 quarters. The position peaked at $191K in Q1 2022. 2 funds tracked by Wall St. Rank hold PEARW as of Q2 2023.

BlackRock reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2023 after selling out during the quarter.
BlackRock sold 233,178 Pear Therapeutics, Inc. Warrant shares in Q2 2023, an estimated $4.45K.
BlackRock first reported a position in Pear Therapeutics, Inc. Warrant in Q4 2021 and held it in 6 quarters.
BlackRock's Pear Therapeutics, Inc. Warrant position peaked at $191K in Q1 2022.
2 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2023.

Based on BlackRock's 13F filing for Q2 2023, filed 11 Aug 2023.